Status:
COMPLETED
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
Lead Sponsor:
ModernaTX, Inc.
Conditions:
SARS-CoV-2
Eligibility:
All Genders
18+ years
Brief Summary
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home. Self...
Eligibility Criteria
Inclusion
- Lives in the continental United States.
- Has been vaccinated against COVID-19 with a U.S.-authorized vaccine (that is, received the single shot J\&J vaccine or both shots in the Pfizer or Moderna series).
- Has received a COVID-19 booster between September 2021 and screening.
- Is willing and able to submit vaccination card photo(s).
- Is willing and able to self-collect capillary blood 3 times during the study period via an at-home whole-blood collection device (that is, the YourBio TAP II Device).
Exclusion
- Has been diagnosed with significant cognitive impairment or dementia.
- Has received more than one COVID-19 vaccine booster at screening.
- Is currently participating in a COVID-19 vaccine clinical trial.
- Is currently receiving chemotherapy or has received chemotherapy in the past 6 months.
- Is currently taking steroids, such as prednisone, for any condition.
- Has been diagnosed with or is taking medications for rheumatoid arthritis (RA), lupus or multiple sclerosis (MS).
- Has received an organ transplant
- Is currently undergoing dialysis of any kind (for example, hemodialysis or chronic ambulatory dialysis) for kidney disease.
Key Trial Info
Start Date :
April 11 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 14 2022
Estimated Enrollment :
1501 Patients enrolled
Trial Details
Trial ID
NCT05367908
Start Date
April 11 2022
End Date
August 14 2022
Last Update
October 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Evidation Health
San Mateo, California, United States, 94402